Exchange Traded Concepts LLC Sells 3,831 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Exchange Traded Concepts LLC cut its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 33,635 shares of the company’s stock after selling 3,831 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Fulgent Genetics were worth $731,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Asset Dedication LLC bought a new stake in Fulgent Genetics during the second quarter valued at approximately $33,000. nVerses Capital LLC bought a new stake in Fulgent Genetics during the second quarter valued at approximately $43,000. Signaturefd LLC lifted its position in Fulgent Genetics by 103.6% during the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in Fulgent Genetics during the second quarter valued at approximately $63,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Fulgent Genetics during the first quarter valued at approximately $178,000. 48.06% of the stock is currently owned by institutional investors.

Fulgent Genetics Stock Performance

Shares of FLGT opened at $19.76 on Friday. The firm has a market cap of $591.30 million, a price-to-earnings ratio of -3.55 and a beta of 1.50. Fulgent Genetics, Inc. has a fifty-two week low of $18.91 and a fifty-two week high of $30.68. The firm has a 50 day moving average price of $21.86 and a 200-day moving average price of $21.48.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. The firm had revenue of $71.03 million during the quarter, compared to analyst estimates of $69.07 million. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.33) EPS. As a group, equities research analysts predict that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.

Insider Transactions at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the sale, the chief executive officer now directly owns 707,275 shares in the company, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.